SRR12202434
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.340
- UV_RESPONSE_DN+0.330
- PROTEIN_SECRETION+0.270
- WNT_BETA_CATENIN_SIGNALING+0.210
- PANCREAS_BETA_CELLS+0.160
- ANGIOGENESIS+0.140
- INFLAMMATORY_RESPONSE+0.140
- APICAL_JUNCTION+0.090
- P53_PATHWAY+0.070
Top 10 suppressed
- E2F_TARGETS-0.470
- G2M_CHECKPOINT-0.430
- CHOLESTEROL_HOMEOSTASIS-0.310
- MYC_TARGETS_V2-0.300
- UV_RESPONSE_UP-0.260
- KRAS_SIGNALING_DN-0.210
- MYC_TARGETS_V1-0.210
- MTORC1_SIGNALING-0.200
- SPERMATOGENESIS-0.200
- APICAL_SURFACE-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 09552358-6d23-4990-858e-908ee5a132f6 | — | — | 0.800 |
| 2 | 102d912c-5882-4ae4-9eaf-cbd2f55f66af | — | — | 0.774 |
| 3 | TCGA-CQ-6221-01A-11R-2081-07 | — | — | 0.761 |
| 4 | TCGA-AC-A2QI-01A-12R-A19W-07 | — | A | 0.752 |
| 5 | SRR26320068 | — | — | 0.744 |
| 6 | TCGA-AR-A24T-01A-11R-A169-07 | — | A | 0.734 |
| 7 | TCGA-B6-A0IH-01A-11R-A115-07 | — | A | 0.731 |
| 8 | C3N-02145 | — | cohortA1 | 0.726 |
| 9 | TCGA-B6-A0RP-01A-21R-A084-07 | — | B | 0.725 |
| 10 | MBCProject_1493_T1_RNA | — | A | 0.719 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.360 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.340 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.330 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.270 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.210 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.140 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.140 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.090 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.070 | Idelalisib | — uncovered |
| APOPTOSIS | 0.060 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.060 | Inavolisib | — uncovered |
| COMPLEMENT | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.050 | Inavolisib | — uncovered |
| COAGULATION | 0.040 | Binimetinib | — uncovered |
| MYOGENESIS | 0.030 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.010 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.010 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.010 | Idelalisib | — uncovered |